Breast cancer is a major cause of cancer-associated deaths in the United States. It was estimated that 12% of women in the U.S. will develop invasive breast cancer in their lifetime. The human epidermal growth factor receptor (HER2/neu) is a growth-promoting protein that is overexpressed in 15–20% of breast cancers (HER2-positive breast cancer). HER2-positive breast cancer generally grows and spreads more quickly than other breast cancers, but it can be targeted therapeutically. Targeting drugs have been developed with a specific design to stop the growth and even the spread of cancer. These drugs include trastuzumab (Herceptin), pertuzumab (Perjeta), ado-trastuzumab emtansine (Kadcyla, or TDM-1), fam-trastuzumab deruxtecan, lapatinib, neratinib and tucatinib. However, the need for better targeted therapy and efficacy still exists. Nanotechnology could have major advantages in terms of detection, targeting, drug delivery, and destruction of cancer cells and tumors. Although a great deal of progress has been accomplished major challenges still need to be addressed. In this review, we examine the major areas of research in the area of nanotechnology and HER2-positive breast cancer.

中文翻译：

---

纳米技术解决HER2阳性乳腺癌的方法

在美国，乳腺癌是癌症相关死亡的主要原因。据估计，美国有12％的女性一生中会患浸润性乳腺癌。人类表皮生长因子受体（HER2 / neu）是一种促进生长的蛋白质，在15-20％的乳腺癌（HER2阳性乳腺癌）中过表达。HER2阳性乳腺癌通常比其他乳腺癌更容易生长和扩散，但可以作为治疗目标。已经开发出具有特定设计的靶向药物，以阻止癌症的生长甚至扩散。这些药物包括曲妥珠单抗（Herceptin），帕妥珠单抗（Perjeta），阿多曲妥珠单抗emtansine（Kadcyla或TDM-1），fam-曲妥珠单抗deruxtecan，拉帕替尼，奈拉替尼和图卡替尼。但是，仍然需要更好的靶向治疗和疗效。纳米技术在检测，靶向，药物输送以及破坏癌细胞和肿瘤方面可能具有主要优势。尽管已经取得了很大进展，但是仍然需要解决主要挑战。在这篇综述中，我们研究了纳米技术和HER2阳性乳腺癌领域的主要研究领域。